title: Long-term Angiogenesis Efficacy Using a Heparin-Conjugated Fibrin (HCF) Delivery System with HBM-MSCs.
abstract: OBJECTIVE
  Heparin-conjugated fibrin (HCF) is suitable for the release and localization of bFGF. We analyzed the effects of a bFGF delivery system using HCF with human bone marrow-derived mesenchymal stem cells (HBM- MSCs) in a dog ischemic limb model.
  
  
  RESULTS
  Animals were divided into HBM-MSCs, HBM-MSCs＋HCF, bFGF-HCF, and HBM-MSCs＋ bFGF-HCF groups. A total of 1×10(7) HBM-MSCs were injected per animal, and the amount of bFGF was 1 mg per dog. Ischemic muscles were harvested at eight weeks and six months after injection of cells. The HBM-MSCs＋ bFGF-HCF group exhibited decreased proportions of capillaries and arterioles six months after transplantation. However, there were more cells positive for the angiogenic factors, VEGF and PDGF, in the eight-week specimens compared with those harvested six months after transplantation.
  
  
  CONCLUSIONS
  Our results demonstrated that a single injection of HBM-MSCs did not have significant long-term angiogenic effects; however, a bFGF delivery system using HCF exerted prolonged angiogenic effects when combined with HBM-MSCs.
authors.affiliation: Division of Vascular Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine.
authors.forename: Ae-Kyeong
authors.initials: AK
authors.lastname: Kim
authors.forename: Min-Hee
authors.initials: MH
authors.lastname: Kim
authors.forename: Byung-Soo
authors.initials: BS
authors.lastname: Kim
authors.forename: Dong-Ik
authors.initials: DI
authors.lastname: Kim
keywords: Angiogenesis; HBM-MSCs; Heparin-conjugated fibrin; Ischemia; Vascular disease